Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 26, No 17 (June 10), 2008: pp. 2890-2894
© 2008 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.15.5465

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Zabierowski, S. E.
Right arrow Articles by Herlyn, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zabierowski, S. E.
Right arrow Articles by Herlyn, M.

REVIEW ARTICLE

Melanoma Stem Cells: The Dark Seed of Melanoma

Susan E. Zabierowski, Meenhard Herlyn

From The Wistar Institute, Philadelphia, PA

Corresponding author: Meenhard Herlyn, DVM, DSc, The Wistar Institute, 3601 Spruce St, Philadelphia, PA 19104; e-mail: herlynm{at}wistar.org

Cells with stem-cell markers and features have recently been identified in melanoma tissues and cell lines. Melanoma stem-like cells possess many traits of tumor-initiating or tumor stem cells including self-renewal capacity, high tumorigenicity, and differentiation into various mesenchymal lineages, including melanocytic cells. Four subpopulations of melanoma-initiating cells have been distinguished: CD20+, CD133+, label-retaining or slow-cycling cells, and side-population cells with high efflux activities. Whether these are distinct or overlapping populations is currently under investigation. Ongoing studies are dissecting and characterizing the hierarchy of these subpopulations within a malignant lesion. Understanding these and the dynamics of clonal dominance will aid in the development of novel therapeutic strategies.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.






About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online